KDM4B: A promising oncology therapeutic target

Cancer Sci. 2024 Jan;115(1):8-16. doi: 10.1111/cas.16005. Epub 2023 Nov 3.

Abstract

Epigenetic modifications are significant in tumor pathogenesis, wherein the process of histone demethylation is indispensable for regulating gene transcription, apoptosis, DNA replication, and repair of damaged DNA. The lysine demethylases (KDMs) serve an essential role in the aforementioned processes, with particular emphasis on the KDM4 family, also referred to as JMJD2. Multiple studies have underscored the significance of the KDM4 family in the regulation of various biological processes including, but not limited to, the cell cycle, DNA repair mechanisms, signaling pathways, and the progression of tumor formation. Nevertheless, it is imperative to elucidate the underlying mechanism of KDM4B, which belongs to the KDM4 gene family. This review presents a comprehensive examination of the structure, mechanism, and function of KDM4B, as well as a critical analysis of the current body of research pertaining to its involvement in tumorigenesis and development. Furthermore, this review explores the potential therapeutic strategies that specifically target KDM4B.

Keywords: KDM4B; cancer therapeutic targets; histone demethylase; oncology; review.

Publication types

  • Review

MeSH terms

  • Cell Cycle
  • DNA Repair / genetics
  • DNA Replication
  • Humans
  • Jumonji Domain-Containing Histone Demethylases / genetics
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Neoplasms* / pathology
  • Signal Transduction

Substances

  • KDM4B protein, human
  • Jumonji Domain-Containing Histone Demethylases